Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
30 May 2024
| m 06:03 | Non-degenerate nucleotides per response element diffhist −54 Marshallsumter talk contribs (→Tabulation of counts) | ||||
28 May 2024
| m 07:35 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Tabulation of counts) | ||||
27 May 2024
|
|
N 23:47 | Template:JR 2 changes history +44 [Jonathan Reyes (2×)] | |||
|
|
23:47 (cur | prev) −25 Jonathan Reyes talk contribs | ||||
| N |
|
22:59 (cur | prev) +69 Jonathan Reyes talk contribs (Created page with "Jonathan Reyes, M.D.[jona3098reyes@gmail.com]") | |||
| N 23:42 | Evinacumab-dgnb diffhist +627 Jonathan Reyes talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...") | ||||
26 May 2024
| m 20:05 | Non-degenerate nucleotides per response element diffhist −50 Marshallsumter talk contribs (→Tabulation of counts) | ||||
25 May 2024
| m 19:41 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Averages per Orders) | ||||
24 May 2024
|
|
m 21:07 | Non-degenerate nucleotides per response element 2 changes history −52 [Marshallsumter (2×)] | |||
| m |
|
21:07 (cur | prev) −52 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
16:55 (cur | prev) 0 Marshallsumter talk contribs (→Averages per Orders) | |||
23 May 2024
|
|
N 14:51 | Glofitamab-gxbm 2 changes history +8,803 [Muhammad Waleed (2×)] | |||
|
|
14:51 (cur | prev) +6,189 Muhammad Waleed talk contribs | ||||
| N |
|
14:40 (cur | prev) +2,614 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...") | |||
|
|
N 14:22 | Rozanolixizumab-noli 2 changes history +8,759 [Muhammad Waleed (2×)] | |||
|
|
14:22 (cur | prev) +5,524 Muhammad Waleed talk contribs | ||||
| N |
|
12:43 (cur | prev) +3,235 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...") | |||
|
|
m 07:03 | Non-degenerate nucleotides per response element 2 changes history −98 [Marshallsumter (2×)] | |||
| m |
|
07:03 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:01 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||